AstraZeneca enters into distribution services agreement with Sun Pharma

17 Nov 2025 Evaluate

AstraZeneca Pharma India (AstraZeneca) has entered into distribution services agreement with Sun Pharmaceutical Industries (Sun Pharma) for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India.

Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma whereas Sun Pharma will promote and distribute the therapy as Gimliand. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorization along with the import license of the molecule.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

9199.00 10.10 (0.11%)
05-Dec-2025 14:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1801.50
Dr. Reddys Lab 1271.95
Cipla 1517.95
Zydus Lifesciences 929.85
Lupin 2092.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×